Session Details
[1S14a]Corporate Planning Symposium: Current status of R&D using strategic modalities in pharmaceutical companies
Mon. Mar 17, 2025 1:40 PM - 3:30 PM JST
Mon. Mar 17, 2025 4:40 AM - 6:30 AM UTC
Mon. Mar 17, 2025 4:40 AM - 6:30 AM UTC
Room 14
Oranizers :Hisaharu Yamada (Mediford Corporation, Dpt. of Pharmacy, Tokyo University of Science) and Teisuke Takahashi (Taisho Pharmaceutical Co., Ltd.)
JPS : Academic Planning Committee for Annual Meeting
Drug development is undergoing a transformation from small molecules to medium molecules and a variety of other modalities. Pharmaceutical companies are making full use of these modalities to devise development strategies that are most effective for applicable diseases. At this symposium, pharmaceutical companies will report on their modality strategies. We believe that it will be an extremely meaningful opportunity for pharmaceutical companies to come together and hear about these modality strategies. What modalities are they considering, and for what diseases? We believe that we will be able to hear from pharmaceutical companies about the characteristics of modalities, the difficulty of development, and other aspects of their field.
[1S14a-1]Multi-Modality Strategy for Creating Innovative Drugs
○Narihiro Toda (Modality Research Laboratories I, Research Function, R&D Division, Daiichi Sankyo Co., Ltd.)
[1S14a-2]Our Strategy to Challenge New Drug Modalities and the Evolution of Small Molecule Drug Discovery
○Ryuichi Totsuka (Mitsubishi Tanabe Pharma Corporation, Research Division, Oncology & Immunology Unit)
[[OD]1S14a-4]Beyond Small Molecules and Biologics: Mid-Size Molecules for Intracellular Tough Targets
○Atsushi Ohta (CHUGAI PHARMACEUTICAL CO., LTD.)